(Reuters) - Pfizer Inc , which in May officially abandoned its bid to buy British rival AstraZeneca Plc , reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines. The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when Pfizer received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis . Excluding special items, Pfizer earned 58 cents per share. ...
via Health News Headlines - Yahoo News http://ift.tt/1pAlHjV
No comments:
Post a Comment